2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

2:30PM-4:00PM: Abstract Number: 2767

Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed

5T091: Patient Outcomes, Preferences, & Attitudes II: Patient Preferences, Beliefs, & Experiences (2762–2767)

2:30PM-4:00PM: Abstract Number: 2773

Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier

5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

2:30PM-4:00PM: Abstract Number: 2733

Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus

5T087: Edmond L. Dubois, MD Memorial Lecture: SLE – Basic Science (2733–2737)

2:30PM-4:00PM: Abstract Number: 2741

Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States

5T088: Genetics, Genomics & Proteomics (2738–2743)

2:30PM-4:00PM: Abstract Number: 2749

Long Non-coding RNA HOTAIR Induces Myofibroblast Activation in Systemic Sclerosis Through EZH2 Dependent De-repression of NOTCH Signalling Pathway Activation

5T095: Systemic Sclerosis & Related Disorder – Basic Science (2744–2749)

2:30PM-4:00PM: Abstract Number: 2788

Longitudinal Changes in the Nasal Microbiome and Disease Activity in Patients with Granulomatosis with Polyangiitis

5T096: Vasculitis – ANCA-Associated II (2786–2791)

2:30PM-4:00PM: Abstract Number: 2753

Major Salivary Gland Ultrasound: Pilot Study of Findings and Feasibility in Childhood-Onset Systemic Lupus Erythematosus (cSLE)

5T089: Imaging of Rheumatic Diseases II (2750–2755)

2:30PM-4:00PM: Abstract Number: 2764

Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis

5T091: Patient Outcomes, Preferences, & Attitudes II: Patient Preferences, Beliefs, & Experiences (2762–2767)

2:30PM-4:00PM: Abstract Number: 2793

Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives

5T101: Clinical Aspects & Outcomes Research (2792–2797)

2:30PM-4:00PM: Abstract Number: 2736

Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus

5T087: Edmond L. Dubois, MD Memorial Lecture: SLE – Basic Science (2733–2737)

2:30PM-4:00PM: Abstract Number: 2789

Neutrophil Extracellular Traps Induce Tissue-Invasive Macrophages in Granulomatosis with Polyangiitis Dominated by Ear, Nose and Throat Manifestations

5T096: Vasculitis – ANCA-Associated II (2786–2791)

2:30PM-4:00PM: Abstract Number: 2758

Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis

5T090: Osteoarthritis – Clinical II: Novel Therapies (2756–2761)

2:30PM-4:00PM: Abstract Number: 2801

Optimal Threshold of Walking Speed Predictive of Mortality Risk over 9 Years in Knee Osteoarthritis: Data from Osteoarthritis Initiative

5T098: Orthopedics, Low Back Pain & Rehabilitation (2798–2803)

2:30PM-4:00PM: Abstract Number: 2766

Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Discrete-Choice Experiment

5T091: Patient Outcomes, Preferences, & Attitudes II: Patient Preferences, Beliefs, & Experiences (2762–2767)

2:30PM-4:00PM: Abstract Number: 2795

Patterns of Ambulatory Health Care Utilization and Medication Adherence Among Transition-Age Youth with Systemic Lupus Erythematosus

5T101: Clinical Aspects & Outcomes Research (2792–2797)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].